Business
Sun BioPharma, Inc. Provides a Business Update and Files Report for Q2 2018
Sun BioPharma, Inc. Provides a Business Update and Files Report for Q2 2018.
About this update from Panbela Therapeutics, Inc.
[{"type":"text","content":"\nFirst Patients Enrolled in Front-Line Combination Study of SBP-101 with Gemcitabine and nab-Paclitaxel for the Treatment of Metastatic Pancreatic CancerAdditional Funds Raised during Q2 MINNEAPOLIS, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (OTCQB:SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of pancreatic diseases, today provides a business update and reports financial results for the quarter ended June 30, 2018.\n Front-Line Combination PDA StudyThe Company’s newest trial, a Phase 1a/1b combination of SBP-101 to be administered with gemcitabine and nab-paclitaxel in previously untreated patients with metastatic pancreatic ductal adenocarcinoma (PDA), enrolled the first patients on June 13, 2018.  Patients were enrolled at the Adelaide Cancer Centre in Adelaide, Australia under the direction of Associate Professor Dusan Kotasek and at the University of Florida Health Cancer Center in Gainesville, Florida under the direction of Thomas J. George, MD, F.A.C.P.  The Phase 1a portion of this study will treat up to 18 PDA patients in three cohorts in order to determine a recommended dose of SBP-101 to be given in combination with standard treatment.  The Phase 1b portion will be an expansion at the recommended dose of SBP-101 and will guide SBP-101’s subsequent development for patients with PDA.  This multi-center, front-line study has 3 sites in Australia, The Austin Health Cancer Trials Centre in Melbourne, The Adelaide Cancer Centre in Adelaide, The Blacktown Cancer and Haematology Centre in Sydney and one site in the United States, The University of Florida Health Cancer Center in Gainesville, Florida. Suzanne Gagnon, MD, Chief Medical Officer for Sun BioPharma, Inc. commented, “The Company and our investigators are excited to have begun this first cohort of patients in the Phase 1a portion of this study.  The clinics are enthusiastic about utilizing SBP-101 in front-line combination for previously untreated patients with metastatic PDA.  We all will be closely monitoring these patients as they move through the protocol for this study.” Partial Close of Private Placement of Common Stock and Warrants During the quarter ended June 30, 2018 the Company entered into Securities Purchase Agreements (the “20...